When cancer spreads to the peritoneum or pleura, patients are in need of better treatment options.
CapnoPharm is dedicated to developing targeted aerosol therapies that reach the disease directly — so patients can live longer, better, and with hope.

CapnoPharm’s approach focuses on delivering therapeutic agents precisely to the site of disease, addressing areas that are difficult to treat with conventional systemic therapies. By prioritizing local delivery, we aim to enhance treatment effectiveness while reducing unnecessary systemic exposure. Guided by rigorous science and a patient-first mindset, CapnoPharm is working to redefine therapeutic possibilities for cancers affecting the peritoneum and pleura.